Ignite Creation Date:
2024-05-06 @ 2:58 AM
Last Modification Date:
2024-10-26 @ 11:26 AM
Study NCT ID:
NCT02171637
Status:
COMPLETED
Last Update Posted:
2014-06-24
First Post:
2014-06-20
Brief Title:
Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Phase I Open Label Dose Escalation Study of Once-daily Oral Treatment With BIBW 2992 for 14 Days in Patients With Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2014-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluation of maximum Tolerated Dose MTD safety pharmacokinetics efficacy of BIBW 2992 pharmacodynamic modulation of biomarkers correlation of Epidermal Growth Factor Receptor EGFR and Human EGF-like Receptor number 2 HER2 immunohistochemical status with objective tumour responses
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None